KCB-328 (C&C Research Labs)
Related Experiment Video
Updated: Oct 4, 2026
09:59
Functional Reconstitution and Channel Activity Measurements of Purified Wildtype and Mutant CFTR Protein
Published on: March 9, 2015
1Ohio State University, Columbus 43210, USA. billman.1@pop.service.ohio-state.edu
Current Opinion in Investigational Drugs (London, England : 2000)
|August 31, 2001
Abstract:
C & C Research Labs is investigating the class III antiarrhythmic KCB-328 as a potential treatment for heart arrhythmia [310688]. The compound is potent in vitro, with little reverse frequency-dependence when compared with E-4031 (qv) and dofetilide (qv) [223384]. KCB-328 is in preclinical development [351687].
